These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 35261196)
1. Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C. Perumalswami PV; Wyatt B; Bowman CA; Patel K; Mageras A; Lewis SC; Branch AD Cancer Med; 2022 May; 11(9):1995-2005. PubMed ID: 35261196 [TBL] [Abstract][Full Text] [Related]
2. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Kramer JR; Cao Y; Li L; Smith D; Chhatwal J; El-Serag HB; Kanwal F Am J Gastroenterol; 2022 Nov; 117(11):1834-1844. PubMed ID: 36327437 [TBL] [Abstract][Full Text] [Related]
3. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. Mueller PP; Chen Q; Ayer T; Nemutlu GS; Hajjar A; Bethea ED; Peters MLB; Lee BP; Janjua NZ; Kanwal F; Chhatwal J J Hepatol; 2022 Jul; 77(1):55-62. PubMed ID: 35157959 [TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis. Rocha C; Doyle EH; Bowman CA; Fiel MI; Stueck AE; Goossens N; Bichoupan K; Patel N; Crismale JF; Makkar J; Lewis S; Perumalswami PV; Schiano TD; Hoshida Y; Schwartz M; Branch AD Cancer Med; 2023 May; 12(9):10175-10186. PubMed ID: 37078924 [TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206 [TBL] [Abstract][Full Text] [Related]
6. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection? Isfordink CJ; Maan R; de Man RA; van Erpecum KJ; van der Meer AJ Eur J Intern Med; 2021 Dec; 94():6-14. PubMed ID: 34563447 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. Chen Q; Ayer T; Adee MG; Wang X; Kanwal F; Chhatwal J JAMA Netw Open; 2020 Nov; 3(11):e2021173. PubMed ID: 33206188 [TBL] [Abstract][Full Text] [Related]
9. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
10. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders. Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751 [TBL] [Abstract][Full Text] [Related]
11. Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals. Chhatwal J; Hajjar A; Mueller PP; Nemutlu G; Kulkarni N; Peters MLB; Kanwal F Clin Gastroenterol Hepatol; 2024 Jan; 22(1):91-101.e6. PubMed ID: 37302445 [TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095 [TBL] [Abstract][Full Text] [Related]
13. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506 [TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841 [TBL] [Abstract][Full Text] [Related]
15. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714 [TBL] [Abstract][Full Text] [Related]
16. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response. Qiu L; Xu S; Qiu Y; Liu Y; Zhang J J Viral Hepat; 2023 Jun; 30(6):559-566. PubMed ID: 36890735 [TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002 [TBL] [Abstract][Full Text] [Related]
18. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents. Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690 [TBL] [Abstract][Full Text] [Related]
19. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C; J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157 [TBL] [Abstract][Full Text] [Related]
20. Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication. Przybyszewski EM; Chung RT J Infect Dis; 2023 Sep; 228(Suppl 3):S226-S231. PubMed ID: 37703341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]